Faron Pharmaceuticals Ltd’s Annual Report 2025 published
Corrected Annual Report 2025 published with previously missing auditor's report included.
Select text to share a quote on X · sign in to keep highlights & notes in your FARN notes
| Faron Pharmaceuticals Ltd | Company announcement | March 04, 2026 at 18:45:00 EET |
TURKU, FINLAND - Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), announces a correction to the company announcement of its Annual Report 2025, originally published on 4 March 2026 at 09:15 EET. The Annual Report 2025 published did not contain the auditor’s report. An updated version of the Annual Report 2025 with the full auditor's report, has been included as an attachment to this announcement.
The English version of Annual Report is available as a PDF file attached to this release and on the company’s website at https://faron.com/investors/reports-and-presentations/. Also the Finnish language version of the Financial Statements is available as a PDF file attached to this release and on the company’s website at https://faron.fi/sijoittajat/raportit-esitykset/.
Faron Pharmaceuticals Ltd
Board of Directors
The BEXMAB study is an open-label Phase I/II clinical trial investigating bexmarilimab in combination with standard of care (SoC) in the aggressive hematological malignancies of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). The primary objective is to determine the safety and tolerability of bexmarilimab in combination with SoC (azacitidine) treatment.
About Bexmarilimab
Bexmarilimab is Faron’s wholly owned, investigational immunotherapy designed to overcome resistance to existing treatments by targeting Clever-1, a receptor on immunosuppressive macrophages and malignant blasts. By inhibiting Clever-1, bexmarilimab reprograms the tumor microenvironment to ignite a potent anti-tumor immune response.
About Faron Pharmaceuticals Ltd.
Faron Pharmaceuticals (AIM: FARN, First North: FARON) is a global, clinical-stage biopharmaceutical company, focused on creating innovative cancer treatments that leverage the patient’s own immune system. The Company’s lead asset bexmarilimab is currently being investigated in multiple clinical trials as a potential therapy for patients with hematological malignancies and solid tumors in combination with other standard treatments.
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.